Bridge Biotherapeutics Reports P-IIa Clinical Trial Results of BBT-401 for the Treatment of Ulcerative Colitis
Shots:
- The P-IIa mid-to-high dose cohort study evaluating the safety & efficacy of BBT-401 (800mg, qd & BID) in 38 patients with active UC at 37 sites in the US, New Zealand, the Republic of Korea, Poland & Ukraine
- The trial failed to meet the primary efficacy EPs of the clinical response rate @57 Days during the induction & extension phases as measured by a reduction of ≥3 points and a ≥30% improvement from the baseline of total Mayo score, clinical response rates for PBO (BID)/ PBO & BBT-401, qd/ BBT-401 (BID) treatment group were 63.6%/54.5%/54.5%, respectively
- The study met its primary safety EPs & the safety and tolerability profile was consistent with the safety profile of BBT-401 (Pellino-1 inhibitor) as in prior studies
Ref: PRNewswire | Image: Bridge Biotherapeutics
Related Post:- Brainomix Collaborated with Bridge Biotherapeutics for BBT-877 to Treat Idiopathic Pulmonary Fibrosis Using AI-Powered e-ILD Software
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
